Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabigatran dual therapy versus warfarin triple therapy after PCI in non-valvular atrial fibrillation
2013-003201-26Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2014
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dabigatran, warfarin, clopidogrel, ticagrelor and aspirin in Atrial fibrillation (AFib) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Time to first ISTH major or clinically relevant non-major bleeding event. Started May 2014; status: completed.
02
Drugs
dabigatranwarfarinclopidogrelticagreloraspirin
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2013-003201-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003201-26.